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Abstract
Background: Fusobacterium species (spp.) bacteremia is uncommon and has been associated with a variety of
clinical presentations. We conducted a retrospective, population based study to determine the relative proportion
of species in this genus causing bacteremia and the risk factors for infection and adverse clinical outcomes.
Methods: All cases of Fusobacterium spp. bacteremia detected at a regional microbiology laboratory serving
outpatient and acute care for a population of approximately 1.3 million people over 11 years were identified from a
computerized database. Clinical data on these cases was extracted from an administrative database and analyzed to
determine underlying risk factors for and outcomes of infection.
Results: There were 72 incident cases of Fusobacterium spp. bacteremia over the study period (0.55 cases/100,000
population per annum). F. nucleatum was the most frequent species (61%), followed by F. necrophorum (25%).
F. necrophorum bacteremia occurred in a younger population without underlying comorbidities and was not
associated with mortality. F. nucleatum bacteremia was found in an older population and was associated with
underlying malignancy or receiving dialysis. Death occurred in approximately 10% of F. nucleatum cases but
causality was not established in this study.
Conclusions: Fusobacterium spp. bacteremia in our community is uncommon and occurs in approximately 5.5
cases per million population per annum. F. necrophorum occurred in an otherwise young healthy population and
was not associated with any mortality. F. nucleatum was found primarily in older patients with chronic medical
conditions and was associated with a mortality of approximately 10%. Bacteremias from other Fusobacterium spp.
were rare.
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Background
Fusobacteria are anaerobic gram-negative rods that are a
rare cause of serious human disease [1,2]. Two Fusobacte-
rium species, F. nucleatum and F. necrophorum, are the
most commonly isolated pathogens within this genus
[2,3]. In 1936 Lemierre described cases of oropharyngeal
infection followed by septic thrombophlebitis of the in-
ternal jugular vein with sepsis syndrome and metastatic
disease, typically to the lungs (a syndrome now eponym-
ously named) [4]. F. necrophorum was identified as the
causal agent of this condition. Carriage of F. necrophorum
in the oropharynx of healthy young adults has been
documented, although it may also play a role in non-
streptococcal tonsillitis [5]. Serious F. necrophorum infec-
tion mostly afflicts young, otherwise healthy, adults [6].
F. nucleatum is a common member of the human oro-
pharyngeal flora, and is an agent in gingival and peri-
odontal disease [7,8]. Of the oral anaerobes, it is also the
most likely to cause extra-oral infections [8]. Metastatic
infections involving the brain [9,10], liver [11,12], joints
[13,14], and heart valves [15] occur albeit rarely. Septic
thrombophelebitis in extra-pharyngeal locations has also
been documented [16,17]. More recently, Han and col-
leagues have been exploring the role of F. nucleatum in
intrauterine infections and preterm birth [18-20]. Not
surprisingly, periodontal disease and dental procedures
are frequently identified as the source of invasive F.
nucleatum infection. Similarly, chemotherapy induced
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oropharyngeal mucositis [21,22] and inflammatory bowel
disease [23,24] have been implicated in invasive F.
nucleatum infection.
Several studies on Fusobacterium infections have pre-
viously been published, including hospital [3,25,26] and
population based studies [1,2,6]. The largest paper from
Hagelskjaer deals specifically with F. necrophorum infec-
tions [1]. Huggan et al. [2] primarily looked at non-
bacteremic cases and the study by Goldberg et al. is
from patients hospitalized at a tertiary care center [3].
As such, the paper by Nohrstrom et al. represents the
only population-based study at present that looks at the
incidence and diseases associated with Fusobacterium
bacteremia as whole [6]. In addition, the relative role of
co-morbidities on the acquisition of Fusobacterium
bacteremia has not yet been teased out. There is also a
wide range of reported mortality: from 5% to 47%. Fur-
ther clarification of these epidemiological characteristics is
best suited to population-based studies. Using such an ap-
proach, this study aims to more clearly define the popula-
tion-based incidence of Fusobacterium bacteremia. We also
sought to better elucidate the risk factors, clinical manifes-
tations, and outcomes of Fusobacterium bacteremia.
Methods
An active, retrospective, population-based surveillance
cohort design for the period of January 1, 2000 to
December 31, 2011 was used for this study to determine
the total incidence, risk factors for, and outcomes of
Fusobacterium spp. bacteremia. The cohort studied
comprised only residents of the Calgary Zone of Alberta
Health Services (AHS), which provides virtually all-
medical and surgical care to 1.3 million people in the
city of Calgary and a large surrounding area in the Prov-
ince of Alberta, Canada. Only patients requiring surgery
for liver, heart, or lung transplantation are routinely
referred elsewhere. More than 95% of all blood cultures
collected in both inpatients and outpatients are
processed by a single laboratory. Results and basic pa-
tient demographic data for all patients were stored in a
single laboratory information system. Detailed data
(including underlying diagnosis and comorbid condi-
tions) was available from patients requiring hospitaliza-
tion to any of the 4 major acute care hospitals in a
hospital administrative database. This data was linked to
create a single surveillance database as previously de-
scribed by Leal et al. [27]. Data on the use of dialysis is
not available for patients less than 18 years of age. Cases
not admitted to hospital were used in the calculation of
age based rates but not for risk factors or outcome
analysis. The Conjoint Health Research Ethics Board at
the University of Calgary and Calgary Zone approved
this study.
A case of Fusobacterium bacteremia was defined by its
isolation from 1 or more sets of aseptically collected
blood cultures. No patient had a second episode during
the study period, and as such there were no duplicate
patients in this study. Isolates confirmed to be
Fusobacterium were speciated using standard microbio-
logic criteria [28] where possible. For those isolates not
speciated by standard methods, partial sequencing of the
16S rRNA gene with MicroSeq 500 kits and an ABI
Prism 3100 sequencer (Applied Biosystems, Foster City,
CA) was performed. Obtained sequences were subject to
a BLAST search against the Integrated Database
Network System (Smartgene Inc, Raleigh NC) bacterial
database to obtain a specific species. Isolates were tested
for antimicrobial susceptibility by gradient diffusion
methodology (Etest, BioMériuex, St. Laurent QC).
Hospital-acquired (HA) bacteremia was defined as
those cases in which the first positive culture was
obtained 48 hours or more after hospital admission, or
within 48 hours of hospital discharge. Healthcare-
associated community onset (HCA) bacteremias were
those cases in which the first positive culture was
obtained in one of the following circumstances: attended
a hospital clinic or emergency department within the
previous 5 to 30 days; admitted to a Calgary Zone acute
care hospital for 2 or more days within the previous
90 days; resident of a nursing home or long-term care
facility; or received outpatient hemodialysis [29]. Com-
munity-acquired (CA) bacteremias were those in which
the first positive culture was obtained less than 48 hours
after hospital admission or were community-onset and
not categorized as HCA.
Analysis was performed using STATA/IC 10.0
(StataCorp, College Station TX). Non-normally distrib-
uted variables were reported as medians with inter-
quartile ranges (IQR). Differences in proportions among
categorical data were assessed using Fisher's exact test
for pair-wise comparisons. The incidence of Fusobacte-
rium bacteremia was calculated by dividing the number
of incident cases by the Calgary Zone population at risk.
The population rates for risk factors evaluated in this
study were estimated or ascertained from local patient
registry data and regional or Canadian survey data as
previously described [27,29]. Risks were expressed as in-
cident rate ratios and reported with 95% confidence in-
tervals. For all statistical comparisons, a p-value ≤ 0.05
considered significant.
Results
During the 11-year study, there were 72 incident cases
of Fusobacterium bacteremia. Basic demographic (age,
gender, residency) and microbiologic data were available
for all cases. Of the ten cases not requiring admission, 3
were F. necrophorum, 5 were F. nucleatum and 2 were
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unspeciated. Age, gender, and further clinical data was
available on 62 patients admitted to one of four acute
care hospitals in the region. Among the 72 incident
Fusobacterium bacteremias, 35 (49%) were community-
acquired, 23 (32%) were healthcare-associated community
onset, and 14 (19%) were hospital-acquired. F. nucleatum
was identified in 44 cases (61%) and, F. necrophorum in
18 cases (25%). Of the remaining 10 cases (14%), 3 were
F. mortiferum, 2 were F. peridonticum, and 5 could only
reliably be identified as Fusobacterium spp.
The overall annual incidence of Fusobacterium
bacteremia was 0.55 per 100,000 population (Figure 1).
Annual variability was seen in keeping with a relatively
rare infection, without any clear pattern evident.
Incidence of F. nucleatum was 0.34/100,000 and F.
necrophorum was 0.14/100,000. Overall median age was
42.1 years. However, a differing pattern of incidence was
evident between F. nucleatum and F. necrophorum
bacteremia (Figure 2). F. nucleatum cases had a median
age of 53.5 years (IQR 36.7-72.0), while F. necrophorum
cases had a median age of 21 years (IQR 18.1-23.4).
There were no cases of F. necrophorum bacteremia in
individuals over the age of 40. Of the 72 incident cases,
45 occurred in men (incidence rate ratio 1.676; 95% con-
fidence interval 1.02-2.81; P = 0.016). Much of the in-
creased risk in men was seen in the elderly (Figure 3).
Among the 62 incident cases with detailed clinical
data, 39 were F. nucleatum, 15 were F. necrophorum,
and the remaining 8 were other Fusobacterium spp.
bacteremia. One or more co-morbidity was present in
39 cases of Fusobacterium bacteremia (63%). The pres-
ence of an underlying co-morbidity was more frequently
seen in cases of F. nucleatum bacteremia (29/39, 74%)
than in cases of F. necrophorum bacteremia (4/15, 27%).
Malignancy and dialysis were the greatest risk factors for
acquiring Fusobacterium bacteremia (Table 1).
The primary diagnoses at the time of F. nucleatum
and F. necrophorum bacteremia are shown in Table 2.
Primary bacteremia, intra-abdominal sepsis, and active
hematological disorder were the most common diagno-
ses in the setting of F. nucleatum bacteremia. F.
necrophorum bacteremia was seen most commonly in
the setting of primary bacteremia and obstetrical-related
infections. Two cases were associated with intravascular
thrombus, but it is unclear if this represents Lemierre’s
disease as that is not coded within the database.
Susceptibility testing results were available for 70
(97%) isolates. All isolates were susceptible to metro-
nidazole and clindamycin. Penicillin resistance was
present in 9% of F. nucleatum isolates and 6% of F.
necrophorum isolates.
Overall mortality was 7/62 (11%). There were no
deaths in patients with F. necrophorum infection. Four
deaths occurred in patients with F. nucleatum bacteremia.
The remaining deaths were in patients with other
Fusobacterium spp.
Discussion
The organization of microbiology diagnostic services in
the Calgary Zone of AHS provides the ability to study
the epidemiology of uncommon infections in this de-
fined population. In the current study, we have found
that the overall incidence of Fusobacterium species
bacteremia is low at 0.55/100,000 per annum. F.
nucleatum bacteremia is over two times more common
than F. necrophorum bacteremia (0.34 versus 0.14/
100,000 per annum respectively). Population-based inci-
dence rates for Fusobacterium bacteremias are scarce in
the literature. Huggan et al. reported their data on inva-
sive Fusobacterium infections from Canterbury region in
New Zealand. They found an incidence of 0.99/100,000
per annum [2]. However, their study is not directly
Figure 1 Annual incidence of Fusobacterium bacteremia by Acquisition Type. CA = community-acquired; HCA = healthcare-associated
community onset; HA = hospital-acquired.
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comparable as only 17% of their cases had bacteremia.
Moreover, very few isolates were identified as F.
nucleatum, with most cases being F. necrophorum or
remaining unspeciated.
Other studies show data more similar to our findings.
A regional study from Finland reported an annual inci-
dence of Fusobacterium bacteremia of 0.55/100,000,
identical to our data [6]. In this study the relative fre-
quency of the two common species was equal (0.22 and
0.23/1000 per annum). Similarly, a prospective trial on
F. necrophorum bacteremia in Denmark showed an inci-
dence of 0.38/100,000 [1].
Both of these studies found a higher rate of F.
necrophorum in their populations compared to our
findings. The most likely explanation is year-to-year
variability in the number of infections in the population.
Another possible explanation for the higher reported in-
cidence in other studies may be due to more consistent
species level microbiological diagnosis in these series.
Unspeciated isolates comprised 7% of our data set,
causing downward bias on our reported species level in-
cidence rates. Though there are some differences on ac-
count of methodological and other factors, our data is
broadly in alignment with previously reported incidence
rates for Fusobacterium bacteremia.
The most striking finding of our study is the absence
of F. necrophorum bacteremia in persons over the age of
40, whereas the incidence of F. nucleatum bacteremia
increased steadily with age (Table 2). F. nucleatum
bacteremia occurred in a group with a median age of
53.5 years compared to 21 years for those with F.
necrophorum bacteremia. In our study, other co-
morbidities were present in 74% of cases of F. nucleatum
bacteremia but in only 27% of those with F.
necrophorum bacteremia. Nohrstrom et al. also report
results similar to ours: the majority of their cases of
F. nucleatum bacteremia were in older patients with
co-morbidities. Likewise, F. necrophorum was seen in
young patients without co-morbidities [6]. This is con-
sistent with the hypothesis that F. necrophorum
Figure 2 Incidence of Fusobacterium bacteremia by species and age group.
Figure 3 Incidence Rates of Fusobacterium bacteremia by age and gender.
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bacteremia is primarily a complication of pharyngitis in
young adults [5].
Previously published population and hospital-based
studies have reported malignancy being a common
co-morbidity in those with F. nucleatum bacteremia
[3,6,25]. However, our quantification of the role of
various co-morbid risk factors on acquisition of Fuso-
bacterium spp. bacteremia is unique in the literature.
We report that malignancy and dialysis significantly in-
crease the risk of acquiring Fusobacterium bacteremia.
Dementia, chronic obstructive lung disease, diabetes,
and heart disease were also risk factors (Table 2).
The underlying diagnosis at the time of bacteremia is
shown in Table 2. Intra-abdominal infection (26%) and
active hematologic disorders (18%) were the most com-
mon primary diagnosis at the time of F. nucleatum
bacteremia. A large proportion of F. nucleatum bacter-
emias did not have a defined focus (31%). A single-
hospital study on F. nucleatum bacteremia from Taiwan
reported primary bacteremia in 39% of cases and an
intra-abdominal source in 12% of cases. However, they
had a far higher proportion of respiratory tract sources at
37% [25]. A recent study by Goldberg et al. from the US
found a 21% thirty day mortality associated with an in-
crease in the serum creatinine and altered level of con-
sciousness [3]. Persons included in this study were
admitted to a tertiary care facility and isolates were not
speciated. The nature of the facility in which this study
was done and a possible increase in F. nucleatum cases in-
cluded may account for their higher observed mortality.
No focus of infection was encoded in our database for
33% of F. necrophorum bacteremias. Of those cases that
did have a defined focus, 20% were obstetrical, and a
combined 26% were thrombotic or pulmonary. These
later cases likely represent Lemierre’s syndrome. Unfor-
tunately our administrative data set does not allow us to
be definitive. F. necrophorum causing obstetrical infec-
tions has been previously reported [2]. We did not see
F. nucleatum obstetrical infections as recently described
by Han et al. [19]. Somewhat contrasting data from
Denmark showed a large group of older patients with F.
necrophorum bacteremia from a gastrointestinal or uro-
genital source [1]. This was not seen in our population.
Our overall mortality was 11% for all Fusobacterium
bacteremia, none of whom had F. necrophorum isolated.
Other population-based studies also report low mortality
rates for Fusobacterium bacteremia: from 1% in New
Zealand [2] to 4% in Finland [6]. Yang et al. reported a
much higher mortality from a single hospital in Taiwan
at 47.4% [25]. This discrepancy is likely due to their
study looking at only F. nucleatum bacteremia. In
addition, their cases were accrued at a tertiary-care cen-
ter with nearly half of them requiring ICU admission.
Fortunately, reduced susceptibility to antibiotics was
uncommon. None of our isolates showed resistance to
metronidazole or clindamycin. Penicillin resistance was
present for both F. nucleatum and F. necrophorum, but at
low levels. This is in keeping with other studies [25,30].
Conclusions
Fusobacterium are a rare cause of serious infection. Our
data confirms from a population-based perspective that
F. necrophorum affects mostly young, healthy adults. In
contrast, F. nucleatum affects older individuals with co-
morbidities, the highest risk being in persons on dialysis
or with underlying malignancy. Fortunately, antibiotic
Table 1 Risk factors for Fusobacterium bacteremia








Malignancy ≥20 10 14.29
(7.28-26.35)
<0.001
Dialysis ≥20 9 14.14
(6.18-28.59)
<0.001








Diabetes ≥1 6 3.24
(1.14-7.51)
0.009
Heart Disease ≥12 7 3.05
(1.17-6.75)
0.007
Alcoholism ≥20 5 2.11
(0.66-5.21)
0.070
Stroke ≥12 1 1.62
(0.04-9.39)
0.296
IRR incidence rate ratio, CI confidence interval.
*Age Group included in analysis of risk factor.
Table 2 Primary diagnosis at time of F. nucleatum and F.
necrophorum bacteremia









No Focus 12 (31) No Focus 5 (33)
Intra-Abdominal
Disease
10 (26) Obstetrical 3 (20)
Hematologic Disorder 7 (18) Other b 3 (20)
Other a 3 (8) Thrombus
Associated
2 (13)





a includes one bone and joint infection, one thrombus-associated infection,
and one pulmonary infection. b includes one skin and soft-tissue infection, one
CNS infection, and one intra-abdominal infection.
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resistance and mortality remains low. Mortality occurs
primarily in patients with F. nucleatum, likely due to as-
sociated co-morbidities.
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